Nothing surprises me in this report. It is as expected i.e. cash is being used to build the generic pipeline. Good to see a little bit of growth on the Evamist and Lenzetto. The real value will come when they commercialise the generic pipeline and when sales start. At the moment, I guess they will be waiting for FDA approval on the 3 products submitted. Once we receive approval i'm sure we will see a licencing agreement soon after.
18m of cash left, looks like this will be enough for another year and a bit. Hopefully sales begins before then and we do not need a capital raise.
- Forums
- ASX - By Stock
- ACR
- Ann: Appendix 4E & Full Year Statutory Accounts
Ann: Appendix 4E & Full Year Statutory Accounts, page-3
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
|
|||||
Last
6.3¢ |
Change
-0.002(3.08%) |
Mkt cap ! $18.31M |
Open | High | Low | Value | Volume |
6.6¢ | 6.6¢ | 6.3¢ | $5.23K | 80.08K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 249878 | 6.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.5¢ | 73455 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 249878 | 0.063 |
1 | 16145 | 0.062 |
1 | 70000 | 0.061 |
1 | 70000 | 0.060 |
1 | 92500 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.065 | 73455 | 1 |
0.070 | 50000 | 1 |
0.072 | 47301 | 1 |
0.073 | 15000 | 2 |
0.075 | 149999 | 1 |
Last trade - 15.55pm 05/07/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |